Prostate Cancer Screening and Dietary Heterocyclic Amines in African American Men
Recruitment status was: Recruiting
RATIONALE: Screening may help doctors find prostate cancer sooner, when it may be easier to treat. The amount of heterocyclic amines in the diet may affect prostate cancer screening results and the risk of prostate cancer.
PURPOSE: This phase II trial is studying prostate cancer screening and dietary heterocyclic amines in African American men.
Other: physiologic testing
Other: study of socioeconomic and demographic variables
Procedure: evaluation of cancer risk factors
Procedure: mutation carrier screening
Procedure: study of high risk factors
|Study Design:||Primary Purpose: Screening|
|Official Title:||Prostate Cancer Screening and Dietary HA Exposure in African-Americans: Phase II|
- Dietary heterocyclic amine (HA) exposure in African American men [ Designated as safety issue: No ]
- Correlation of HA exposure with prostate cancer screening results [ Designated as safety issue: No ]
|Study Start Date:||March 2002|
- Estimate dietary heterocyclic amine (HA) exposure in African American men who use HA-forming meats and cooking methods.
- Correlate dietary HA exposure with prostate-specific antigen and digital rectal exam screening results (i.e., higher HA exposure with increased abnormality in prostate cancer screening results) in these participants.
OUTLINE: This is a prospective study.
Participants complete a routine medical questionnaire and undergo a detailed dietary interview that focuses on meat consumption, cooking preferences, and other factors that may be associated with prostate cancer risk. Participants then undergo a digital rectal exam (DRE) and blood collection for prostate-specific antigen (PSA) testing (total PSA and % free PSA). Results of PSA testing and DRE, including follow-up instructions (if needed), are sent to the participant 3-4 weeks later.
Blood samples are also examined by phenotypic assays for UV-damage induced nucleotide excision-repair capacity.
PROJECTED ACCRUAL: A total of 800 participants will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00354497
|United States, California|
|Lawrence Livermore National Laboratory at University of California|
|Livermore, California, United States, 94550|
|Alta Bates Summit Medical Center - Summit Campus|
|Oakland, California, United States, 94609|
|Principal Investigator:||Kenneth T. Bogen, DrPH, MPH, MA, ScD||Lawrence Livermore National Laboratory at University of California|